Follow us on:

Linkedin Facebook

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

AstraZeneca

AstraZeneca Plc completes equity investment with Cellectis

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...
GSK Plc

GSK PLC reports Strong 1st quarter results with Sales and Earnings Growth

GSK PLC's Q1 2024 results show impressive growth in sales, profits, and earnings. CEO Emma Walmsley highlights strong performance and future growth prospects...
Haleon

Haleon plc Reports Resilient Q1 2024 Performance Despite Market Challenges

Haleon plc (NYSE/LON:HLN) impresses with solid Q1 results, showcasing organic revenue growth despite market challenges. Explore key sectors and financial highlights here. #Haleon #ConsumerHealth..
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals PLC provides Trading Update and Future Growth Outlook

Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
Haleon plc

Haleon plc appoints Dawn Allen as Chief Financial Officer

Haleon plc appoints Dawn Allen as Chief Financial Officer, effective 28 October 2024. Tobias Hestler to step down due to health condition...
GSK plc

GSK Plc’s Shingrix maintains High Protection against Shingles for over a decade

GSK plc released promising data on Shingrix vaccine showing high protection against shingles for over a decade in adults over 50. Key findings and implications are detailed in this report...
GSK plc

GSK’s 5-in-1 MenABCWY meningococcal vaccine candidate FDA Review accepted

GSK's MenABCWY vaccine candidate aims to simplify immunization against invasive meningococcal disease. Learn more about this promising development here...
AstraZeneca

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...
AstraZeneca

AstraZeneca Plc’s Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...
intravenous (IV) line

AstraZeneca’s Imfinzi shows positive results in Phase III trial for small cell lung cancer

AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...
AstraZeneca

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...
AstraZeneca

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...
AstraZeneca

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...
GSK

GSK announces positive results from DREAMM-8 phase III trial for Blenrep

GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...
Convatec Group

ConvaTec Group reports accelerating organic revenue growth of 7.2%

ConvaTec Group plc (LON:CTEC) reports strong annual results with 7.2% organic revenue growth, margin expansion and new product launches...
GSK

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
intravenous (IV) line

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...
Haleon plc

Haleon delivers strong organic growth of 8%, with Q4 organic growth over 6%

Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...
GSK

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...
AstraZeneca

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

AstraZeneca

AstraZeneca Plc completes equity investment with Cellectis

AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...
GSK Plc

GSK PLC reports Strong 1st quarter results with Sales and Earnings Growth

GSK PLC's Q1 2024 results show impressive growth in sales, profits, and earnings. CEO Emma Walmsley highlights strong performance and future growth prospects...
Haleon

Haleon plc Reports Resilient Q1 2024 Performance Despite Market Challenges

Haleon plc (NYSE/LON:HLN) impresses with solid Q1 results, showcasing organic revenue growth despite market challenges. Explore key sectors and financial highlights here. #Haleon #ConsumerHealth..
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals PLC provides Trading Update and Future Growth Outlook

Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and momentum across the Group in 2024...
Haleon plc

Haleon plc appoints Dawn Allen as Chief Financial Officer

Haleon plc appoints Dawn Allen as Chief Financial Officer, effective 28 October 2024. Tobias Hestler to step down due to health condition...
GSK plc

GSK Plc’s Shingrix maintains High Protection against Shingles for over a decade

GSK plc released promising data on Shingrix vaccine showing high protection against shingles for over a decade in adults over 50. Key findings and implications are detailed in this report...
GSK plc

GSK’s 5-in-1 MenABCWY meningococcal vaccine candidate FDA Review accepted

GSK's MenABCWY vaccine candidate aims to simplify immunization against invasive meningococcal disease. Learn more about this promising development here...
AstraZeneca

AstraZeneca Plc to increase Dividend by 7% for 2024

AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...
AstraZeneca

AstraZeneca Plc’s Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...
intravenous (IV) line

AstraZeneca’s Imfinzi shows positive results in Phase III trial for small cell lung cancer

AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...
AstraZeneca

AstraZeneca’s Voydeya approved in the US as add-on therapy for PNH patients with EVH

AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment...
AstraZeneca

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here...
AstraZeneca

AstraZeneca expands late-stage rare disease pipeline with Amolyt Pharma acquisition

AstraZeneca plc (LON:AZN) has entered an agreement to acquire Amolyt Pharma, focusing on treatments for rare endocrine diseases, including hypoparathyroidism...
GSK

GSK announces positive results from DREAMM-8 phase III trial for Blenrep

GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...
Convatec Group

ConvaTec Group reports accelerating organic revenue growth of 7.2%

ConvaTec Group plc (LON:CTEC) reports strong annual results with 7.2% organic revenue growth, margin expansion and new product launches...
GSK

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...
intravenous (IV) line

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...
Haleon plc

Haleon delivers strong organic growth of 8%, with Q4 organic growth over 6%

Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...
GSK

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...
AstraZeneca

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple